About Us
We are inspired by a simple vision: the delivery of new, powerful fully diagnostic imaging tools, that radically improve the outcomes of those with cancer. The result is NanoMark - the world's most advanced MR imaging agent, enabling safe, early, non-invasive and unambiguous detection of solid cancers.
NanoMark: Advanced Imaging With NO COMPromises
Contrast
ZERO RADIOACTIVITY & Safe to Use
Resolution
NanoMark delivers the highest possible contrast, differentiating the smallest cancers from healthy tissue.
Resolution
ZERO RADIOACTIVITY & Safe to Use
Resolution
NanoMark provides the highest resolution of all imaging modalities, highlighting the smallest cancers and metastases.
ZERO RADIOACTIVITY & Safe to Use
ZERO RADIOACTIVITY & Safe to Use
ZERO RADIOACTIVITY & Safe to Use
NanoMark Imaging does not use radioactive sources, simplifying regulatory challenges. The imaging agent is safe and quickly exits the body.
Targeted to Cancer
Capability already in place
ZERO RADIOACTIVITY & Safe to Use
NanoMark uniquely targets only solid tumor cancer cells - only imaging where the cancer is.
Quantitative
Capability already in place
Capability already in place
NanoMark imaging is quantitative, providing new diagnostic information on tumor structure and behavior.
Capability already in place
Capability already in place
Capability already in place
No new equipment is required. NanoMark leverages existing MRI machines currently available.
Addressing a Broad Need
Patients
Four out of ten people in the US will be diagnosed with cancer in their lifetime. The earlier it is caught, the higher the likelihood of a successful outcome. The founders of Kuva have personally experienced the loss of loved ones from cancer. We developed NanoMark to removing any diagnostic ambiguity that patients anguish over today, and lead to better outcomes.
Physicians
Doctors can only react to the information available. Even with the battery of tests currently available, cancer broadly speaking is elusive. Better data ensures better outcomes, even if it means ending treatments for those who cannot benefit from it.
Payors
Cancer treatments and/or surgery are expensive, and ongoing care is costly. The ability to reduce costs by accurately identifying cancer early is the best cost saving tool available. The earlier and more accurately cancer is detected, will favorably improve economics and outcomes.